$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000117887918000009 Filed on August 07, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2018 Q1
Revenue	$20.60M	$21.31M	$16.70M
YoY Change	89.41%	197.69%	300.38%
Cost Of Revenue	$4.310M	$3.135M	$2.615M
YoY Change	140.78%	195.48%	235.26%
Gross Profit	$16.29M	$18.17M	$14.08M
YoY Change	79.28%	198.08%	315.37%
Gross Profit Margin	79.07%	85.29%	84.34%
Selling, General & Admin	$31.87M	$29.17M	$27.40M
YoY Change	47.21%	51.06%	43.21%
% of Gross Profit	195.67%	160.52%	194.56%
Research & Development	$138.2M	$34.66M	$40.80M
YoY Change	240.12%	8.36%	32.12%
% of Gross Profit	848.75%	190.71%	289.74%
Depreciation & Amortization	$1.073M	$973.0K	$969.0K
YoY Change	26.09%	19.83%	18.17%
% of Gross Profit	6.59%	5.35%	6.88%
Operating Expenses	$172.5M	$65.11M	$70.26M
YoY Change	-39.34%	22.47%	26.83%
Operating Profit	-$156.2M	-$46.93M	-$56.18M
YoY Change	-43.25%	-0.28%	8.02%
Interest Expense	$4.715M	$4.560M	$4.488M
YoY Change	8.37%	9.12%	-227.14%
% of Operating Profit
Other Income/Expense, Net	-$1.039M	-$5.316M	$2.764M
YoY Change	-150.83%	-321.5%	353.11%
Pretax Income	-$159.2M	-$61.49M	-$51.31M
YoY Change	-42.39%	27.88%	-6.61%
Income Tax	-$51.00K	$339.0K	-$1.392M
% Of Pretax Income
Net Earnings	-$159.2M	-$61.83M	-$49.92M
YoY Change	42.53%	28.45%	-9.23%
Net Earnings / Revenue	-772.79%	-290.17%	-298.97%
Basic Earnings Per Share
Diluted Earnings Per Share	-$841.4K	-$327.8K	-$283.7K
COMMON SHARES
Basic Shares Outstanding	189.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$564.4M	$539.0M	$562.5M
YoY Change	37.16%	137.24%	101.04%
Cash & Equivalents	$201.8M	$73.31M	$114.3M
Short-Term Investments	$362.6M	$465.6M	$448.2M
Other Short-Term Assets	$16.20M	$2.400M	$10.60M
YoY Change	161.29%	-60.0%	-1.85%
Inventory	$6.311M	$7.769M	$8.100M
Prepaid Expenses
Receivables	$14.19M	$15.08M	$10.80M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$601.0M	$576.2M	$592.0M
YoY Change	39.45%	139.1%	99.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.66M	$9.111M	$8.900M
YoY Change	11.03%	-13.23%	-8.25%
Goodwill	$197.8M	$197.8M
YoY Change	0.0%
Intangibles	$23.00M	$23.00M
YoY Change
Long-Term Investments		$13.80M	$42.70M
YoY Change
Other Assets	$6.099M	$5.915M	$5.600M
YoY Change	45.21%	97.17%	93.1%
Total Long-Term Assets	$237.6M	$249.7M	$278.0M
YoY Change	-4.9%	-64.23%	-60.13%
TOTAL ASSETS
Total Short-Term Assets	$601.0M	$576.2M	$592.0M
Total Long-Term Assets	$237.6M	$249.7M	$278.0M
Total Assets	$838.6M	$825.9M	$870.0M
YoY Change	23.18%	-12.05%	-12.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$54.30M	$41.60M	$43.70M
YoY Change	1.12%	16.85%	10.35%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$65.88M	$52.96M	$140.7M
YoY Change	-3.4%	-47.41%	28.38%
LONG-TERM LIABILITIES
Long-Term Debt	$318.8M	$169.4M	$166.8M
YoY Change	97.28%	6.41%	6.31%
Other Long-Term Liabilities	$3.029M	$2.770M	$34.50M
YoY Change	-90.56%	-98.84%	-85.76%
Total Long-Term Liabilities	$3.029M	$2.770M	$201.3M
YoY Change	-98.44%	-99.3%	-49.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$65.88M	$52.96M	$140.7M
Total Long-Term Liabilities	$3.029M	$2.770M	$201.3M
Total Liabilities	$427.6M	$264.0M	$348.4M
YoY Change	57.74%	-60.72%	-48.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.334B	-$1.175B	$383.0K
YoY Change
Common Stock	$1.733B	$1.726B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$411.0M	$561.9M	$521.6M
YoY Change
Total Liabilities & Shareholders Equity	$838.6M	$825.9M	$870.0M
YoY Change	23.18%	-12.05%	-12.42%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2018 Q1
OPERATING ACTIVITIES
Net Income	-$159.2M	-$61.83M	-$49.92M
YoY Change	42.53%	28.45%	-9.23%
Depreciation, Depletion And Amortization	$1.073M	$973.0K	$969.0K
YoY Change	26.09%	19.83%	18.17%
Cash From Operating Activities	-$132.8M	-$57.00M	-$49.52M
YoY Change	171.49%	35.97%	-0.64%
INVESTING ACTIVITIES
Capital Expenditures	-$2.690M	-$1.060M	$819.0K
YoY Change	140.18%	-31.61%	-212.19%
Acquisitions
YoY Change
Other Investing Activities	$117.2M	$11.78M	-$181.8M
YoY Change	-167.81%	-73.87%	98.28%
Cash From Investing Activities	$114.5M	$10.72M	-$182.6M
YoY Change	-165.82%	-75.38%	97.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$294.6M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	146.8M	7.030M	$296.6M
YoY Change	-41.32%	-173.84%	-296679.0%
NET CHANGE
Cash From Operating Activities	-132.8M	-57.00M	-$49.52M
Cash From Investing Activities	114.5M	10.72M	-$182.6M
Cash From Financing Activities	146.8M	7.030M	$296.6M
Net Change In Cash	128.5M	-39.25M	$65.32M
YoY Change	369.6%	397.47%	-145.88%
FREE CASH FLOW
Cash From Operating Activities	-$132.8M	-$57.00M	-$49.52M
Capital Expenditures	-$2.690M	-$1.060M	$819.0K
Free Cash Flow	-$130.1M	-$55.94M	-$50.34M
YoY Change	172.23%	38.57%	2.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	189134863	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	AMICUS THERAPEUTICS INC
	fold	Capital Lease Obligations Incurred Funded By Capital Lease Borrowings CapitalLeaseObligationsIncurredFundedByCapitalLeaseBorrowings	0	USD
	fold	Capital Lease Obligations Incurred Funded By Capital Lease Borrowings CapitalLeaseObligationsIncurredFundedByCapitalLeaseBorrowings	81000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	358998000	USD
CY2018Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	553244000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2018Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	15000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	437000	USD
CY2018Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	471000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	358562000	USD
CY2018Q2	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	552788000	USD
	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	3003000	USD
	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-2107000	USD
	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	0	USD
	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-5000000	USD
	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	496000	USD
	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	457000	USD
	fold	Non Cash Deferred Taxes And Other Tax Benefits NonCashDeferredTaxesAndOtherTaxBenefits	98000	USD
	fold	Non Cash Deferred Taxes And Other Tax Benefits NonCashDeferredTaxesAndOtherTaxBenefits	0	USD
CY2017Q2	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	10000000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	351000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	1003000	USD
	us-gaap	Depreciation Depreciation	1636000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2226000	USD
	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	2027000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6043000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	351000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3449000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	515000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	793000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2103000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5273000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11567000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6341000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13819000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4715000	USD
	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	10000000	USD
CY2018Q2	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	0	USD
	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	0	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	53890000	USD
CY2018Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	41613000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9464000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15077000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12515000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14415000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-436000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-455000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-1659000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-1539000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1400758000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1723865000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5537000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	64111000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	63043000	shares
CY2017Q4	us-gaap	Assets Assets	627024000	USD
CY2018Q2	us-gaap	Assets Assets	825889000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	391965000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	576230000	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	311700000	USD
CY2018Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	482158000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	15000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	437000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	471000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	309938000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	479933000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	309502000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	479500000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	479477000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5628000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1400000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	25400000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	26800000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8400000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8600000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	17000000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	18200000	USD
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	166989790	shares
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187026000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37394000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49060000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73311000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73300000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	49060000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	73311000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187413000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37787000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51237000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75441000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-149626000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	24204000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	189053214	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	166989790	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	189053214	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1721000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	1939000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49969000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-105337000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59103000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-111267000	USD
CY2017Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	164167000	USD
CY2018Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	169440000	USD
CY2017Q2	us-gaap	Cost Of Revenue CostOfRevenue	1061000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1836000	USD
CY2018Q2	us-gaap	Cost Of Revenue CostOfRevenue	3135000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	5750000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	295100000	USD
CY2018Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	406500000	USD
CY2017	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2017Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	2258000	USD
CY2018Q2	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	2731000	USD
CY2017Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	7750000	USD
CY2018Q2	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	2750000	USD
CY2017Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	14156000	USD
CY2018Q2	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	14156000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6465000	USD
CY2018Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6465000	USD
CY2017Q2	us-gaap	Depreciation Depreciation	812000	USD
CY2018Q2	us-gaap	Depreciation Depreciation	973000	USD
	us-gaap	Depreciation Depreciation	1942000	USD
CY2018Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	88300000	USD
CY2018Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	507400000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.72
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	614000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1016000	USD
CY2017Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1050000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-5628000	USD
CY2018Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-300000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1400000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	269722000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	274300000	USD
CY2017Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	265350000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	25400000	USD
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	26500000	USD
CY2018Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	26800000	USD
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	265000	USD
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-2739000	USD
CY2017Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7600000	USD
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7600000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2700000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2739000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	8000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2017Q4	us-gaap	Goodwill Goodwill	197797000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	197797000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	6097000	USD
	us-gaap	Gross Profit GrossProfit	9491000	USD
CY2018Q2	us-gaap	Gross Profit GrossProfit	18174000	USD
	us-gaap	Gross Profit GrossProfit	32255000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48087000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-103024000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61494000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-112804000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	49000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	105000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	339000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1053000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4297000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11801000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4584000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3650000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3774000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	780000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	825889000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	4179000	USD
	us-gaap	Interest Expense InterestExpense	8469000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	4560000	USD
	us-gaap	Interest Expense InterestExpense	9048000	USD
CY2018Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2263000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	4623000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	7769000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3843000	USD
CY2018Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5506000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	753000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1512000	USD
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	2913000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4650000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	274174000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	263994000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	627024000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	70040000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	52963000	USD
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	27658000	USD
CY2018Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	29531000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	309502000	USD
CY2018Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	465641000	USD
CY2017Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0	USD
CY2018Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	13836000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9619000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	303612000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48864000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-171876000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-91757000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106516000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-48136000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-103129000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-61833000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-111751000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	53158000	USD
	us-gaap	Operating Expenses OperatingExpenses	108568000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	65105000	USD
	us-gaap	Operating Expenses OperatingExpenses	135368000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-47061000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-99077000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-46931000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2770000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-103113000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5200000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2400000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3010000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5316000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5915000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-155000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-72000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	422000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-19000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1678000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2136000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2308000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	503000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0	USD
CY2018Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-109000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-109000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1833000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2208000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2730000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	484000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2346000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2554000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	28000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	184494000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	380234000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2279000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1881000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19316000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14432000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	294600000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	294584000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	137909000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	210239000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1554000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7580000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3617000	USD
	us-gaap	Profit Loss ProfitLoss	-103129000	USD
	us-gaap	Profit Loss ProfitLoss	-111751000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9062000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9111000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	142000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	142000	USD
CY2017Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	31985000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	62861000	USD
CY2018Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	34660000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38443000	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29172000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	56568000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11567000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7158000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11327000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	21309000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	38005000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19311000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	75458000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	387000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	393000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2177000	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2130000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1063610000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	383000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1174978000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	13819000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	7000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.45
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	20239839	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	352850000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	561895000	USD
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	16076000	USD
CY2018Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	13063000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	143000718	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	142886614	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	188621423	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	182303128	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its accounts receivable related to its product sales of GALAFOLD. The Company’s accounts receivable at </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> have arisen from product sales primarily in the EU. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred any credit losses.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001178879-18-000009-index-headers.html	Edgar Link	pending
0001178879-18-000009-index.html	Edgar Link	pending
0001178879-18-000009.txt	Edgar Link	pending
0001178879-18-000009-xbrl.zip	Edgar Link	pending
amicus-06302018x10q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fold-06302018xex311.htm	Edgar Link	pending
fold-06302018xex312.htm	Edgar Link	pending
fold-06302018xex321.htm	Edgar Link	pending
fold-20180630.xml	Edgar Link	completed
fold-20180630.xsd	Edgar Link	pending
fold-20180630_cal.xml	Edgar Link	unprocessable
fold-20180630_def.xml	Edgar Link	unprocessable
fold-20180630_lab.xml	Edgar Link	unprocessable
fold-20180630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2018 Q3 Form 10-Q Financial Statement

#000117887918000009 Filed on August 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2018 Q3 Form 10-Q Financial Statement

#000117887918000009 Filed on August 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold